Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact.

Literature DB >> 25146527

Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact.

John W Davis¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2014 PMID： 25146527 DOI： 10.1111/bju.12695

Source DB: PubMed Journal: BJU Int ISSN： 1464-4096 Impact factor: 5.588

Keyword Cloud
Cited

× No keyword cloud information.

10 in total

Review 1. [Molecular biomarkers and prognostic factors for prostate cancer].

Authors: A Kretschmer; Y Tolkach; J Ellinger; G Kristiansen
Journal: Urologe A Date: 2017-07 Impact factor: 0.639

2. LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality.

Authors: Valentina Fiano; Daniela Zugna; Chiara Grasso; Morena Trevisan; Luisa Delsedime; Luca Molinaro; Anna Gillio-Tos; Franco Merletti; Lorenzo Richiardi
Journal: Epigenetics Date: 2016-11-28 Impact factor: 4.528

3. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.

Authors: Scott A Tomlins; Mohammed Alshalalfa; Elai Davicioni; Nicholas Erho; Kasra Yousefi; Shuang Zhao; Zaid Haddad; Robert B Den; Adam P Dicker; Bruce J Trock; Angelo M DeMarzo; Ashley E Ross; Edward M Schaeffer; Eric A Klein; Cristina Magi-Galluzzi; R Jeffrey Karnes; Robert B Jenkins; Felix Y Feng
Journal: Eur Urol Date: 2015-05-08 Impact factor: 20.096

Review 4. Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.

Authors: A E Ross; A V D'Amico; S J Freedland
Journal: Prostate Cancer Prostatic Dis Date: 2015-06-30 Impact factor: 5.554

5. External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer.

Authors: David Tiberi; George Rodrigues; Tom Pickles; Jim Morris; Juanita Crook; Andre-Guy Martin; Fabio Cury; Charles Catton; Himu Lukka; Andrew Warner; Daniel Taussky
Journal: Can Urol Assoc J Date: 2017 Mar-Apr Impact factor: 1.862

6. A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men.

Authors: Adam B Murphy; Samuel Carbunaru; Oluwarotimi S Nettey; Chase Gornbein; Michael A Dixon; Virgilia Macias; Roohollah Sharifi; Rick A Kittles; Ximing Yang; Andre Kajdacsy-Balla; Peter Gann
Journal: Urology Date: 2020-04-08 Impact factor: 2.649

Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact.

Review 1. [Molecular biomarkers and prognostic factors for prostate cancer].

2. LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality.

3. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.

Review 4. Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.

5. External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer.

6. A 17-Gene Panel Genomic Prostate Score Has Similar Predictive Accuracy for Adverse Pathology at Radical Prostatectomy in African American and European American Men.

7. Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer.

8. Automated analysis of co-localized protein expression in histologic sections of prostate cancer.

Review 9. Quality of care and economic considerations of active surveillance of men with prostate cancer.

Review 10. Precision medicine applications in prostate cancer.